March 26, 2018 / 6:54 AM / a month ago

BRIEF-RaQualia Pharma says license agreement for novel P2X7 receptor antagonist

Reuters Staff

1 Min Read

March 26(Reuters) - RaQualia Pharma Inc

* Says it and Asahi Kasei Pharma Corp have entered into a license agreement for a novel P2X7 receptor antagonist discovered through a research collaboration between the two companies

Source text in Japanese:goo.gl/TJ8sZH

Further company coverage: (Beijing Headline News)

Our Standards:The Thomson Reuters Trust Principles.

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.